Scientific advisors Last update: June 2024.
Author: alcyon
John C. Bell, PhD
Scientific advisor John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically… Continue reading John C. Bell, PhD
Pedro Romero, MD
Scientific advisor Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer. Previously,… Continue reading Pedro Romero, MD
produits : TG6050 – en
TG6050 TG6050, an innovative oncolytic virus from the Invir.IO® platform, armed oncolytic virus given by intravenous administration. TG6050 has been engineered to express human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody. Discover how TG6050 works A novel immunotherapy TG6050 is based on a patented viral… Continue reading produits : TG6050 – en
annoncegb4001
TG4001 Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers Read the press release – Download the presentation Watch our analyst call discussing the results
Transgene R&D Day (Paris, France)
Lien
annonceR&D
Find Out How Transgene’s Virus Powered ImmunotherapiesCan Transform the Treatment of Solid Tumors R&D Day – ParisSeptember 27, 2022 Detailed Program – Watch the webcast – Presentation
TG4050
TG4050 TG4050 is an individualized therapeutic vaccine A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate. –> article annonce 28362 ou substitut 28368 Collaboration agreements Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each… Continue reading TG4050
annonce TG4050en
Clinical Proof of Principlein head and neck cancer All treated patients remain disease-free after a median follow up of 24.1 months Press release [PDF] Poster presented at SITC 2024 Listen to Dr. Alessandro Riva’s comments, Chairman & CEO of Transgene (VOST) Liste to the KOL Event TG4050 (April, 2023) (in English) One cancer, one… Continue reading annonce TG4050en
Carol Stuckley
Independent Director Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of… Continue reading Carol Stuckley